Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

PHASE2RecruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

BRCA-Mutated Breast CarcinomaHER2-negative Breast Cancer

Interventions

DRUG

HRS-1167

a highly selective PARP1 inhibitor

DRUG

Famitinib

a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit

DRUG

Camrelizumab

a humanised anti-programmed death-1 (anti PD-1) antibody

Trial Locations (1)

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER